FetUS: Technical Feasibility Study of Ultrasound Muscle Imaging in Antenatal Ultrasound

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06130592
Collaborator
(none)
230
2
13

Study Details

Study Description

Brief Summary

The objective of the study is to evaluate the performance of muscle ultrasound sections on antenatal ultrasound between 21-24 amenorrhea weeks for the screening of muscle atrophy, in a sample of low-risk and high-risk pregnancies of congenital multiple arthrogryposis

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: ultrasound muscle imaging technique
N/A

Detailed Description

Frequent rare diseases (100-200 births in France / year), congenital multiple arthrogryposis include a set of pathologies characterized by the limitation of joint movements at least two joint levels.Their functional prognosis and muscle atrophy are often severe after birth.

Routine ultrasound call signs are either non-specific or insensitive and difficult to detect due to time constraints. Antenatal ultrasound screening is not very effective for these pathologies, which are often particularly serious.

The main criterion will be the success rate of realization of all four ultrasound sections at the extremities (deltoide, biceps, quadriceps, triceps) and measurements of the distances "skin - muscle fascia" and "muscular fascia - periosteum" between 21-24 amenorrhea weeks

Study Design

Study Type:
Interventional
Anticipated Enrollment :
230 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
study prospective,randomized ,two groups (low risk of AMC vs hight risk of AMC), multicentrestudy prospective,randomized ,two groups (low risk of AMC vs hight risk of AMC), multicentre
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Technical Feasibility Study of Ultrasound Muscle Imaging in Antenatal Ultrasound Screening of Congenital Multiple Arthrogryposis
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: high risk of Arthrogryposis AMC

Patient with a diagnosis during the 1st, 2nd, or 3rd trimester ultrasound, of an abnormality of position / deformation of one or more joints, and / or an abnormality of fetal movements at screening ultrasound or interrogation

Diagnostic Test: ultrasound muscle imaging technique
ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis

Active Comparator: low risk of Arthrogryposis AMC

Patient coming for screening ultrasound

Diagnostic Test: ultrasound muscle imaging technique
ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis

Outcome Measures

Primary Outcome Measures

  1. Rate of achievement (success) of all four sections at the extremities [72 hours +/- 24 hours]

    Rate of achievement (success) of all four sections at the extremities for measurements (in mm) of the distances "skin - muscular aponeurosis" and "muscular aponeurosis- periosteum" between 21-24 amenorrhea weeks

Secondary Outcome Measures

  1. Rate of achievement (success) of each four sections [72 hours +/- 24 hours]

    Rate of achievement (success) of measurements (in mm) of the distances "skin - muscular aponeurosis" and "muscular aponeurosis- periosteum" between 21-24 amenorrhea weeks for biceps, deltoide, quadriceps and sural triceps

  2. Collect the raisons for the failure of achievement of all sections [72 hours +/- 24 hours]

    Collect the raisons for the failure of achievement of all sections (Inadequate foetal position,Insufficient echogenicity, Reasons related to the position of the limbs (full extension or flexion of the elbows or knees, abduction of the shoulder, other), other raison (to be specified)

  3. Duration of realization of the ultrasound sections [72 hours +/- 24 hours]

    Duration of realization of the ultrasound sections (investigators make an hypotheses of a duration of 3 minutes necessary for the realization of the sections

  4. Comparison of the completion rates of all cuts during ultrasounds between high- and low-risk patients [72 hours +/- 24 hours]

    Comparison of the completion rates of all cuts during ultrasounds between high- and low-risk patients

  5. Concordance of measures (CCI coefficient) will be evaluated in intra-observer and inter-observer respectively [72 hours +/- 24 hours]

    Concordance of measures (CCI coefficient) will be evaluated in intra-observer and inter-observer respectively by dividing by half the high-risk pregnancies, to whom it will be proposed a 2nd ultrasound of the 2nd trimester, within 3 days (±24) hours by the same / another referent sonographer in the same center. A group of 30 low-risk pregnancies will be evaluated in the same way, with the study of intra-observer reproducibility in 15. The sample of 30 pregnancies in which two measurements are made makes it possible to obtain a lower bound of the 95% confidence interval of the intra-class correlation coefficient greater than 0.7, if this coefficient is 0.85 or more. This threshold is usually considered to reflect a satisfactory concordance.

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 55 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Any pregnant woman consulting in one of the two obstetric gynecology departments in connection with the CPDPN (Multidisciplinary Prenatal Diagnostic Centers) of the University hospitals of Lyon or Grenoble.

  • Mono-embryonic pregnancy.

  • Gestational ages retained on the first dating ultrasound or the 1st trimester ultrasound between 21-24 amenorrhea weeks.

  • For women at "high risk": diagnosis during ultrasound of the 1st, 2nd, or 3rd trimesters, of an abnormality of position / deformation of one or more joints, and / or an abnormality of fetal movements on screening ultrasound or interrogation (population group at "high risk of AMC").

  • Regulatory criteria: adults, affiliated to a social security scheme, having signed a consent

Exclusion Criteria:
  • Multiple pregnancies, and / or non-progressive .

  • Obese women (BMI > 30 in early pregnancy)

  • Subject in a period of exclusion from another study

  • Subject under administrative or judicial supervision

  • Subject who cannot be contacted in case of emergency

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Grenoble

Investigators

  • Principal Investigator: Klaus DIETERICH, MD,PhD, Univ. Grenoble Alpes Inserm U1209 IAB CHU Grenoble Alpes

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT06130592
Other Study ID Numbers:
  • 38RC21.0423
First Posted:
Nov 14, 2023
Last Update Posted:
Nov 14, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2023